Broad Solid Tumor
Conditions
Keywords
First line NSCLC
Brief summary
The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself, in combination with Nivolumab, and in combination with both nivolumab and ipilimumab in participants with solid cancers that are advanced or have spread.
Interventions
DRUGBMS-986207
Specified dose on specified days
BIOLOGICALNivolumab
Specified dose on specified days
BIOLOGICALIpilimumab
Specified dose on specified days
Sponsors
Ono Pharmaceutical Co. Ltd
Bristol-Myers Squibb
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must have pre-existing or prior programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) results within 3 months of enrollment from testing of tumor tissue; PD-L1 expression must be tumor cell positive ≥ 1% for a participant to be eligible for enrollment * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria; radiographic tumor assessment performed within 28 days before randomization
Exclusion criteria
* Primary central nervous system (CNS) disease, or tumors with CNS metastases as the only site of disease. Controlled brain metastases will be allowed to enroll * Other active malignancy requiring concurrent intervention * Uncontrolled or significant cardiovascular disease * Active, known, or suspected autoimmune disease * NSCLC without prior treatment in the advanced or metastatic setting (Part 2C) Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Adverse Events | From first dose (Day 1) untill 100 days after last dose (Up to approximately 27 months) | An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization. |
| Number of Participants Who Died | From first dose (Day 1) untill 100 days after last dose (Up to approximately 27 months) | Participants who died with any cause are considered in the analysis. |
| Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | From first dose (Day 1) and up to 6 weeks | Criteria for Dose-Limiting Toxicities (DLTs): Hepatic DLTs (excluding HCC): Grade (Gr) 4 elevations in AST, ALT, ALP, or total bilirubin. Gr 3 elevations in AST, ALT, or ALP \>5 days, with symptoms, or bilirubin \>2xULN without cholestasis. Gr 2 AST or ALT with symptomatic liver inflammation. AST or ALT \>3xULN and bilirubin \>2xULN without cholestasis. Hepatic DLTs for HCC: AST or ALT \>10xULN for \>2 weeks. AST or ALT \>15xULN. Total bilirubin \>8xULN (elevated at entry) or \>5xULN (normal at entry). ALT ≥10xULN and bilirubin ≥2xULN or baseline, without other causes. Hematologic DLTs: Gr 4 neutropenia ≥7 days. Gr 4 thrombocytopenia. Gr 3 thrombocytopenia with bleeding or platelet transfusion. Febrile neutropenia. Gr 3 hemolysis requiring intervention. Gr 4 anemia not due to underlying disease. Dermatologic DLTs: Gr 4 rash. Gr 3 rash not improving to ≤Gr 1 after 1-2 week delay. Other DLTs: Gr 2-4 eye issues, Gr 3-4 toxicities, excluding specific Gr 3 events like nausea, fever. |
| Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | From first dose (Day 1) till 100 days after last dose (Up to approximately 27 months) | Blood samples were collected to assess the abnormalities in laboratory parameters. The laboratory parameters were graded by Common Terminology Criteria for Adverse Events (CTCAE). Grade 3=Severe; Grade 4=Life-threatening. |
| Part 2C: Objective Response Rate (ORR) | From first dose (Day 1) and up to 24 weeks | ORR is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
| Part 2C: Duration of Response (DOR) | From first dose (Day 1) and up to 24 weeks | DOR is defined for participants who have a confirmed CR or PR as the date from first documented CR or PR per RECIST v1.1 to the date of the documentation of disease progression or death due to any cause, whichever is earlier. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
| Part 2C: Progression Free Survival Rate at Week 24 | Week 24 | Progression Free Survival Rates at 24 weeks is defined as the percentage of participants who achieve PFS at 24 weeks. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks) | Blood samples were collected for assessing AUC (TAU). |
| BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks) | Blood samples were collected for assessing Ctau. |
| BMS-986207 Total Body Clearance (CLT) | Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks) | Blood samples were collected for assessing CLT. |
| Objective Response Rate (ORR) | From first dose (Day 1) and up to 24 weeks | ORR is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters |
| BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks) | Blood samples were collected for assessing AI\_TAU. |
| Number of Participants With Positive Anti-BMS-986207-Antibodies Results | From first dose (Day 1) till 100 days after last dose (Up to approximately 27 months) | Participants who were treated with BMS-986207 and at least one post-baseline evaluable ADA assessment were considered in the analysis |
| BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks) | Blood samples were collected for assessing Css-avg. |
| Duration of Response | From first dose (Day 1) and up to 24 weeks | DOR is defined for participants who have a confirmed CR or PR as the date from first documented CR or PR per RECIST v1.1 to the date of the documentation of disease progression or death due to any cause, whichever is earlier. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
| Progression Free Survival Rate at Week 24 | Week 24 | Progression Free Survival Rates at 24 weeks is defined as the percentage of participants who achieve PFS at 24 weeks. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. |
| Maximum Observed Concentration (Cmax) of BMS-986207 | Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks) | Cmax is defined as maximum plasma concentration of the drug. |
| BMS-986207 Time to Maximum Concentration (Tmax) | Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks) | Time to observed maximum concentration (Tmax) is defined as the amount of time in hours for a drug to reach the maximum concentration after administration. |
| BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks) | Blood samples were collected for assessing T-HALFeff. Exposure measure includes AUC\[TAU\]. |
| BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks) | BMS-986207 area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)). |
Countries
Argentina, Australia, Canada, Chile, Japan, Romania, Singapore, United States
Participant flow
Pre-assignment details
Participants were not randomized in Part 2B arm.
Participants by arm
| Arm | Count |
|---|---|
| Part 1A BMS-986207 Safety Run In Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks). | 1 |
| Part 1A BMS-986207 20 mg Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w). | 2 |
| Part 1A BMS-986207 80 mg Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w). | 3 |
| Part 1A BMS-986207 240 mg Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 240 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w). | 4 |
| Part 1A BMS-986207 800 mg Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 800 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w). | 8 |
| Part 1A BMS-986207 1600 mg Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w) or 2 doses of BMS-986207 administered every 4 weeks (q4w). | 4 |
| Part 2A BMS-986207 800 mg (CRC) Participants with colorectal cancer (CRC) were administered with 800 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w). | 20 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every q2w. Participants were also administered with Nivolumab 240 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q2w. | 4 |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 240 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every q2w. Participants were also administered with Nivolumab 240 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q2w. | 4 |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered q4w. Participants were also administered with Nivolumab 480 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q4w. | 4 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg Participants with CRC or ovarian cancer or hepatocellular carcinoma were administered with 480 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered q4w. Participants were also administered with Nivolumab 480 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q4w. | 18 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with Nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and Ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the Nivolumab infusion. | 6 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the nivolumab infusion. | 18 |
| Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg Participants with first-line non-small cell lung cancer were administered with 600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the nivolumab infusion. | 5 |
| Total | 101 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 | FG013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | ADVERSE EVENT UNRELATED TO STUDY DRUG | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Overall Study | DISEASE PROGRESSION | 1 | 2 | 2 | 4 | 6 | 4 | 19 | 3 | 4 | 4 | 11 | 5 | 14 | 3 |
| Overall Study | Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Overall Study | Other reasons | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Overall Study | STUDY DRUG TOXICITY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Part 1A BMS-986207 Safety Run In | Part 1A BMS-986207 20 mg | Part 1A BMS-986207 80 mg | Part 1A BMS-986207 240 mg | Part 1A BMS-986207 800 mg | Part 1A BMS-986207 1600 mg | Part 2A BMS-986207 800 mg (CRC) | Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 55.0 years | 70.0 years STANDARD_DEVIATION 2.83 | 61.0 years STANDARD_DEVIATION 6.24 | 65.5 years STANDARD_DEVIATION 12.61 | 56.4 years STANDARD_DEVIATION 13.99 | 59.3 years STANDARD_DEVIATION 9.43 | 60.1 years STANDARD_DEVIATION 10.16 | 66.5 years STANDARD_DEVIATION 3.11 | 48.8 years STANDARD_DEVIATION 8.85 | 56.3 years STANDARD_DEVIATION 19.57 | 63.9 years STANDARD_DEVIATION 13.19 | 67.8 years STANDARD_DEVIATION 10.03 | 56.9 years STANDARD_DEVIATION 12.68 | 67.4 years STANDARD_DEVIATION 8.91 | 60.7 years STANDARD_DEVIATION 11.96 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 1 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants | 2 Participants | 3 Participants | 3 Participants | 5 Participants | 3 Participants | 11 Participants | 3 Participants | 3 Participants | 3 Participants | 16 Participants | 4 Participants | 15 Participants | 1 Participants | 73 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants | 1 Participants | 7 Participants | 1 Participants | 1 Participants | 1 Participants | 2 Participants | 1 Participants | 1 Participants | 3 Participants | 22 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants | 1 Participants | 3 Participants | 0 Participants | 1 Participants | 2 Participants | 1 Participants | 1 Participants | 10 Participants | 0 Participants | 22 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 0 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) White | 1 Participants | 2 Participants | 2 Participants | 4 Participants | 6 Participants | 3 Participants | 15 Participants | 4 Participants | 3 Participants | 2 Participants | 16 Participants | 2 Participants | 7 Participants | 5 Participants | 72 Participants |
| Sex: Female, Male Female | 1 Participants | 2 Participants | 2 Participants | 2 Participants | 4 Participants | 2 Participants | 9 Participants | 3 Participants | 1 Participants | 2 Participants | 4 Participants | 3 Participants | 9 Participants | 1 Participants | 45 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 4 Participants | 2 Participants | 11 Participants | 1 Participants | 3 Participants | 2 Participants | 14 Participants | 3 Participants | 9 Participants | 4 Participants | 56 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 1 | 0 / 2 | 3 / 3 | 2 / 4 | 5 / 8 | 2 / 4 | 15 / 20 | 2 / 4 | 4 / 4 | 4 / 4 | 7 / 18 | 3 / 6 | 13 / 18 | 3 / 5 |
| other Total, other adverse events | 1 / 1 | 2 / 2 | 3 / 3 | 4 / 4 | 8 / 8 | 4 / 4 | 20 / 20 | 3 / 4 | 4 / 4 | 4 / 4 | 18 / 18 | 6 / 6 | 18 / 18 | 5 / 5 |
| serious Total, serious adverse events | 1 / 1 | 0 / 2 | 3 / 3 | 3 / 4 | 5 / 8 | 1 / 4 | 11 / 20 | 3 / 4 | 2 / 4 | 1 / 4 | 6 / 18 | 4 / 6 | 11 / 18 | 5 / 5 |
Outcome results
Primary
Number of Participants Who Died
Participants who died with any cause are considered in the analysis.
Time frame: From first dose (Day 1) untill 100 days after last dose (Up to approximately 27 months)
Population: All Treated Participants.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A BMS-986207 Safety Run In | Number of Participants Who Died | 1 Participants |
| Part 1A BMS-986207 20 mg | Number of Participants Who Died | 0 Participants |
| Part 1A BMS-986207 80 mg | Number of Participants Who Died | 3 Participants |
| Part 1A BMS-986207 240 mg | Number of Participants Who Died | 1 Participants |
| Part 1A BMS-986207 800 mg | Number of Participants Who Died | 1 Participants |
| Part 1A BMS-986207 1600 mg | Number of Participants Who Died | 1 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Number of Participants Who Died | 8 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Number of Participants Who Died | 2 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Number of Participants Who Died | 2 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Number of Participants Who Died | 1 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Number of Participants Who Died | 1 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants Who Died | 1 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants Who Died | 3 Participants |
| Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants Who Died | 1 Participants |
Primary
Number of Participants With Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose (Day 1) untill 100 days after last dose (Up to approximately 27 months)
Population: All Treated Participants.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A BMS-986207 Safety Run In | Number of Participants With Adverse Events | Participants with any Adverse Events | 1 Participants |
| Part 1A BMS-986207 Safety Run In | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 1 Participants |
| Part 1A BMS-986207 20 mg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 0 Participants |
| Part 1A BMS-986207 20 mg | Number of Participants With Adverse Events | Participants with any Adverse Events | 2 Participants |
| Part 1A BMS-986207 20 mg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 0 Participants |
| Part 1A BMS-986207 80 mg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 0 Participants |
| Part 1A BMS-986207 80 mg | Number of Participants With Adverse Events | Participants with any Adverse Events | 3 Participants |
| Part 1A BMS-986207 80 mg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 3 Participants |
| Part 1A BMS-986207 240 mg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 3 Participants |
| Part 1A BMS-986207 240 mg | Number of Participants With Adverse Events | Participants with any Adverse Events | 4 Participants |
| Part 1A BMS-986207 240 mg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 0 Participants |
| Part 1A BMS-986207 800 mg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 0 Participants |
| Part 1A BMS-986207 800 mg | Number of Participants With Adverse Events | Participants with any Adverse Events | 8 Participants |
| Part 1A BMS-986207 800 mg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 5 Participants |
| Part 1A BMS-986207 1600 mg | Number of Participants With Adverse Events | Participants with any Adverse Events | 4 Participants |
| Part 1A BMS-986207 1600 mg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 1 Participants |
| Part 1A BMS-986207 1600 mg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Number of Participants With Adverse Events | Participants with any Adverse Events | 20 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 11 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 3 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Number of Participants With Adverse Events | Participants with any Adverse Events | 4 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 2 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 1 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Number of Participants With Adverse Events | Participants with any Adverse Events | 4 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 1 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Number of Participants With Adverse Events | Participants with any Adverse Events | 4 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 6 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 1 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Number of Participants With Adverse Events | Participants with any Adverse Events | 18 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 4 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Adverse Events | Participants with any Adverse Events | 6 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 1 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Adverse Events | Participants with any Adverse Events | 18 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 3 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 11 Participants |
| Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Adverse Events | AEs leading to treatment discontinuation | 3 Participants |
| Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Adverse Events | Participants with Serious Adverse Events | 5 Participants |
| Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Adverse Events | Participants with any Adverse Events | 5 Participants |
Primary
Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities
Criteria for Dose-Limiting Toxicities (DLTs): Hepatic DLTs (excluding HCC): Grade (Gr) 4 elevations in AST, ALT, ALP, or total bilirubin. Gr 3 elevations in AST, ALT, or ALP \>5 days, with symptoms, or bilirubin \>2xULN without cholestasis. Gr 2 AST or ALT with symptomatic liver inflammation. AST or ALT \>3xULN and bilirubin \>2xULN without cholestasis. Hepatic DLTs for HCC: AST or ALT \>10xULN for \>2 weeks. AST or ALT \>15xULN. Total bilirubin \>8xULN (elevated at entry) or \>5xULN (normal at entry). ALT ≥10xULN and bilirubin ≥2xULN or baseline, without other causes. Hematologic DLTs: Gr 4 neutropenia ≥7 days. Gr 4 thrombocytopenia. Gr 3 thrombocytopenia with bleeding or platelet transfusion. Febrile neutropenia. Gr 3 hemolysis requiring intervention. Gr 4 anemia not due to underlying disease. Dermatologic DLTs: Gr 4 rash. Gr 3 rash not improving to ≤Gr 1 after 1-2 week delay. Other DLTs: Gr 2-4 eye issues, Gr 3-4 toxicities, excluding specific Gr 3 events like nausea, fever.
Time frame: From first dose (Day 1) and up to 6 weeks
Population: All Treated Participants. Pre-specified to be only collected for Part 1A, 1B, 1C and 2A arms.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 2 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities | 1 Participants |
Primary
Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities
Blood samples were collected to assess the abnormalities in laboratory parameters. The laboratory parameters were graded by Common Terminology Criteria for Adverse Events (CTCAE). Grade 3=Severe; Grade 4=Life-threatening.
Time frame: From first dose (Day 1) till 100 days after last dose (Up to approximately 27 months)
Population: All treated participants with available laboratory abnormality results. Pre-specified to be only collected for Part 1A, 1B, 1C and 2A arms.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 1 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 1 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 1 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 Safety Run In | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1A BMS-986207 20 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 1 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 80 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 1 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 1 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 1 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 1 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 1 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 1 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 1 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 2 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 1 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 2 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 1 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1A BMS-986207 800 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 1 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 1 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1A BMS-986207 1600 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 2 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 1 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 4 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 4 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 7 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 1 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 2 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 1 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 1 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 1 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 1 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 1 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 2 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 2 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 1 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 1 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 1 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 1 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 1 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 1 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 1 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 1 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 2 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 1 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 1 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 1 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 2 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 1 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 1 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 1 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 1 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 1 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 3) | 2 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CALCIUM (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | CREATININE (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LIPASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ABSOLUTE NEUTROPHIL COUNT (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 3) | 4 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALANINE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | NEUTROPHILS (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | APTT (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | G-GLUTAMYL TRANSFERASE (Grade 3) | 3 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERNATREMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LEUKOCYTES (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 3) | 1 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 3) | 1 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERKALEMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALBUMIN (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERCALCEMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HEMOGLOBIN (Grade 3) | 2 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | BILIRUBIN, TOTAL (Grade 3) | 1 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOKALEMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | AMYLASE (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ASPARTATE AMINOTRANSFERASE (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPERMAGNESEMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | LYMPHOCYTES (ABSOLUTE) (Grade 3) | 2 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PHOSPHORUS (Grade 3) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOCALCEMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | ALKALINE PHOSPHATASE (Grade 3) | 1 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | URIC ACID (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPONATREMIA (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | PLATELET COUNT (Grade 4) | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities | HYPOMAGNESEMIA (Grade 4) | 0 Participants |
Primary
Part 2C: Duration of Response (DOR)
DOR is defined for participants who have a confirmed CR or PR as the date from first documented CR or PR per RECIST v1.1 to the date of the documentation of disease progression or death due to any cause, whichever is earlier. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose (Day 1) and up to 24 weeks
Population: All Treated Participants. Participants with CR or PR were included in the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A BMS-986207 Safety Run In | Part 2C: Duration of Response (DOR) | NA months |
Primary
Part 2C: Objective Response Rate (ORR)
ORR is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose (Day 1) and up to 24 weeks
Population: All Treated Participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1A BMS-986207 Safety Run In | Part 2C: Objective Response Rate (ORR) | 20.0 percentage of participants |
Primary
Part 2C: Progression Free Survival Rate at Week 24
Progression Free Survival Rates at 24 weeks is defined as the percentage of participants who achieve PFS at 24 weeks. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Week 24
Population: All Treated Participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1A BMS-986207 Safety Run In | Part 2C: Progression Free Survival Rate at Week 24 | 80.0 percentage of participants |
Secondary
BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T))
BMS-986207 area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)).
Time frame: Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)
Population: All treated participants who have evaluable concentration-time data were included in the analysis. Only participants with evaluable concentration-time data at particular timepoint are considered in the analysis. Participant in Part 1A BMS-986207 Safety Run In did not meet criteria of evaluable concentration-time data hence not included in the analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A BMS-986207 Safety Run In | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 903246 h*ng/mL | Geometric Coefficient of Variation 16 |
| Part 1A BMS-986207 Safety Run In | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 2 Day 1 | 1433844 h*ng/mL | — |
| Part 1A BMS-986207 20 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 4040645 h*ng/mL | Geometric Coefficient of Variation 20 |
| Part 1A BMS-986207 20 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 2 Day 1 | 8631703 h*ng/mL | — |
| Part 1A BMS-986207 80 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 11778859 h*ng/mL | Geometric Coefficient of Variation 27 |
| Part 1A BMS-986207 80 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 2 Day 1 | 21669222 h*ng/mL | Geometric Coefficient of Variation 46 |
| Part 1A BMS-986207 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 39736190 h*ng/mL | Geometric Coefficient of Variation 26 |
| Part 1A BMS-986207 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 2 Day 1 | 79172947 h*ng/mL | Geometric Coefficient of Variation 31 |
| Part 1A BMS-986207 800 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 2 Day 1 | 151321351 h*ng/mL | Geometric Coefficient of Variation 17 |
| Part 1A BMS-986207 800 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 66647788 h*ng/mL | Geometric Coefficient of Variation 15 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 2 Day 1 | 74976626 h*ng/mL | Geometric Coefficient of Variation 45 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 33053505 h*ng/mL | Geometric Coefficient of Variation 37 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 4954133 h*ng/mL | Geometric Coefficient of Variation 63 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 2 Day 1 | 5329459 h*ng/mL | Geometric Coefficient of Variation 43 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 7568790 h*ng/mL | Geometric Coefficient of Variation 58 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 2 Day 1 | 16061212 h*ng/mL | — |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 103780934 h*ng/mL | Geometric Coefficient of Variation 21 |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 3 Day 1 | 113248878 h*ng/mL | — |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 3 Day 1 | 42867360 h*ng/mL | Geometric Coefficient of Variation 24 |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 26213882 h*ng/mL | Geometric Coefficient of Variation 34 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 3 Day 1 | 133901271 h*ng/mL | Geometric Coefficient of Variation 49 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 55152586 h*ng/mL | Geometric Coefficient of Variation 79 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 34199336 h*ng/mL | Geometric Coefficient of Variation 38 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 3 Day 1 | 56012897 h*ng/mL | Geometric Coefficient of Variation 46 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 3 Day 1 | 53257007 h*ng/mL | Geometric Coefficient of Variation 82 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T)) | Cycle 1 Day 1 | 38608827 h*ng/mL | Geometric Coefficient of Variation 34 |
Secondary
BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU)
Blood samples were collected for assessing AUC (TAU).
Time frame: Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)
Population: All treated participants who have evaluable concentration-time data were included in the analysis. Only participants with evaluable concentration-time data at particular timepoint are considered in the analysis. Participant in Part 1A BMS-986207 Safety Run In did not meet criteria of evaluable concentration-time data hence not included in the analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A BMS-986207 Safety Run In | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 903246 h*ng/mL | Geometric Coefficient of Variation 16 |
| Part 1A BMS-986207 Safety Run In | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 2 Day 1 | 1433844 h*ng/mL | — |
| Part 1A BMS-986207 20 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 2 Day 1 | 8631703 h*ng/mL | — |
| Part 1A BMS-986207 20 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 4040645 h*ng/mL | Geometric Coefficient of Variation 20 |
| Part 1A BMS-986207 80 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 2 Day 1 | 21669222 h*ng/mL | Geometric Coefficient of Variation 46 |
| Part 1A BMS-986207 80 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 11778859 h*ng/mL | Geometric Coefficient of Variation 27 |
| Part 1A BMS-986207 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 42372351 h*ng/mL | Geometric Coefficient of Variation 16 |
| Part 1A BMS-986207 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 2 Day 1 | 75841795 h*ng/mL | Geometric Coefficient of Variation 35 |
| Part 1A BMS-986207 800 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 2 Day 1 | 151321351 h*ng/mL | Geometric Coefficient of Variation 17 |
| Part 1A BMS-986207 800 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 66647788 h*ng/mL | Geometric Coefficient of Variation 15 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 36019071 h*ng/mL | Geometric Coefficient of Variation 29 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 2 Day 1 | 72506970 h*ng/mL | Geometric Coefficient of Variation 42 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 5436490 h*ng/mL | Geometric Coefficient of Variation 49 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 2 Day 1 | 6228807 h*ng/mL | Geometric Coefficient of Variation 14 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 7962140 h*ng/mL | Geometric Coefficient of Variation 46 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 2 Day 1 | 16061212 h*ng/mL | — |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 3 Day 1 | 113248878 h*ng/mL | — |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 107854224 h*ng/mL | Geometric Coefficient of Variation 27 |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 3 Day 1 | 44114081 h*ng/mL | Geometric Coefficient of Variation 23 |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 27192752 h*ng/mL | Geometric Coefficient of Variation 27 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 85887190 h*ng/mL | Geometric Coefficient of Variation 28 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 3 Day 1 | 124674549 h*ng/mL | Geometric Coefficient of Variation 38 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 35370530 h*ng/mL | Geometric Coefficient of Variation 35 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 3 Day 1 | 56012897 h*ng/mL | Geometric Coefficient of Variation 46 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 3 Day 1 | 53257007 h*ng/mL | Geometric Coefficient of Variation 82 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU) | Cycle 1 Day 1 | 38608827 h*ng/mL | Geometric Coefficient of Variation 34 |
Secondary
BMS-986207 Average Concentration Over a Dosing Interval (Css-avg)
Blood samples were collected for assessing Css-avg.
Time frame: Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)
Population: All treated participants who have evaluable concentration-time data were included in the analysis. Only participants with evaluable concentration-time data at particular timepoint are considered in the analysis. Participant in Part 1A BMS-986207 Safety Run In did not meet criteria of evaluable concentration-time data hence not included in the analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A BMS-986207 Safety Run In | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 2 Day 1 | 4281 ng/mL | — |
| Part 1A BMS-986207 20 mg | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 2 Day 1 | 25746 ng/mL | — |
| Part 1A BMS-986207 80 mg | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 2 Day 1 | 64581 ng/mL | Geometric Coefficient of Variation 46 |
| Part 1A BMS-986207 240 mg | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 2 Day 1 | 225882 ng/mL | Geometric Coefficient of Variation 35 |
| Part 1A BMS-986207 800 mg | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 2 Day 1 | 451954 ng/mL | Geometric Coefficient of Variation 17 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 2 Day 1 | 209969 ng/mL | Geometric Coefficient of Variation 46 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 2 Day 1 | 18650 ng/mL | Geometric Coefficient of Variation 15 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 2 Day 1 | 48112 ng/mL | — |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 3 Day 1 | 168655 ng/mL | — |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 3 Day 1 | 67521 ng/mL | Geometric Coefficient of Variation 23 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 3 Day 1 | 247899 ng/mL | Geometric Coefficient of Variation 37 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 3 Day 1 | 113134 ng/mL | Geometric Coefficient of Variation 46 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 3 Day 1 | 103591 ng/mL | Geometric Coefficient of Variation 78 |
| Unknown | BMS-986207 Average Concentration Over a Dosing Interval (Css-avg) | Cycle 1 Day 1 | — ng/mL | — |
Secondary
BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff)
Blood samples were collected for assessing T-HALFeff. Exposure measure includes AUC\[TAU\].
Time frame: Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)
Population: All treated participants who have evaluable concentration-time data were included in the analysis. Only participants with evaluable concentration-time data at particular timepoint are considered in the analysis. Participant in Part 1A BMS-986207 Safety Run In did not meet criteria of evaluable concentration-time data hence not included in the analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A BMS-986207 Safety Run In | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 2 Day 1 | 189 hours | — |
| Part 1A BMS-986207 20 mg | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 2 Day 1 | 334 hours | — |
| Part 1A BMS-986207 80 mg | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 2 Day 1 | 319 hours | Geometric Coefficient of Variation 26 |
| Part 1A BMS-986207 240 mg | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 2 Day 1 | 306 hours | Geometric Coefficient of Variation 43 |
| Part 1A BMS-986207 800 mg | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 2 Day 1 | 344 hours | Geometric Coefficient of Variation 3 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 2 Day 1 | 338 hours | Geometric Coefficient of Variation 14 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 2 Day 1 | 293 hours | Geometric Coefficient of Variation 11 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 2 Day 1 | 317 hours | — |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 3 Day 1 | 372 hours | — |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 3 Day 1 | 390 hours | Geometric Coefficient of Variation 32 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 3 Day 1 | 317 hours | — |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 3 Day 1 | 294 hours | Geometric Coefficient of Variation 16 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 3 Day 1 | 722 hours | — |
| Unknown | BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff) | Cycle 1 Day 1 | — hours | — |
Secondary
BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau)
Blood samples were collected for assessing Ctau.
Time frame: Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)
Population: All treated participants who have evaluable concentration-time data were included in the analysis. Only participants with evaluable concentration-time data at particular timepoint are considered in the analysis. Participant in Part 1A BMS-986207 Safety Run In did not meet criteria of evaluable concentration-time data hence not included in the analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A BMS-986207 Safety Run In | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 1657 ng/mL | Geometric Coefficient of Variation 24 |
| Part 1A BMS-986207 Safety Run In | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 2 Day 1 | 2790 ng/mL | — |
| Part 1A BMS-986207 20 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 6526 ng/mL | Geometric Coefficient of Variation 41 |
| Part 1A BMS-986207 20 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 2 Day 1 | 18500 ng/mL | — |
| Part 1A BMS-986207 80 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 20264 ng/mL | Geometric Coefficient of Variation 34 |
| Part 1A BMS-986207 80 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 2 Day 1 | 43315 ng/mL | Geometric Coefficient of Variation 45 |
| Part 1A BMS-986207 240 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 79783 ng/mL | Geometric Coefficient of Variation 18 |
| Part 1A BMS-986207 240 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 2 Day 1 | 157016 ng/mL | Geometric Coefficient of Variation 48 |
| Part 1A BMS-986207 800 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 2 Day 1 | 383682 ng/mL | Geometric Coefficient of Variation 37 |
| Part 1A BMS-986207 800 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 118571 ng/mL | Geometric Coefficient of Variation 29 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 2 Day 1 | 136133 ng/mL | Geometric Coefficient of Variation 54 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 51893 ng/mL | Geometric Coefficient of Variation 53 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 5875 ng/mL | Geometric Coefficient of Variation 31 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 2 Day 1 | 11449 ng/mL | Geometric Coefficient of Variation 24 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 9560 ng/mL | Geometric Coefficient of Variation 158 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 2 Day 1 | 34400 ng/mL | — |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 66597 ng/mL | Geometric Coefficient of Variation 44 |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 3 Day 1 | 83300 ng/mL | — |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 3 Day 1 | 34396 ng/mL | Geometric Coefficient of Variation 43 |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 17353 ng/mL | Geometric Coefficient of Variation 56 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 3 Day 1 | 149964 ng/mL | Geometric Coefficient of Variation 23 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 75172 ng/mL | Geometric Coefficient of Variation 36 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 26556 ng/mL | Geometric Coefficient of Variation 54 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 3 Day 1 | 61568 ng/mL | Geometric Coefficient of Variation 53 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 3 Day 1 | 37051 ng/mL | Geometric Coefficient of Variation 272 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau) | Cycle 1 Day 1 | 22879 ng/mL | Geometric Coefficient of Variation 61 |
Secondary
BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU)
Blood samples were collected for assessing AI\_TAU.
Time frame: Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)
Population: All treated participants who have evaluable concentration-time data were included in the analysis. Only participants with evaluable concentration-time data at particular timepoint are considered in the analysis. Participant in Part 1A BMS-986207 Safety Run In did not meet criteria of evaluable concentration-time data hence not included in the analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A BMS-986207 Safety Run In | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 2 Day 1 | 1.42 Ratio | — |
| Part 1A BMS-986207 20 mg | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 2 Day 1 | 2.00 Ratio | — |
| Part 1A BMS-986207 80 mg | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 2 Day 1 | 1.94 Ratio | Geometric Coefficient of Variation 17 |
| Part 1A BMS-986207 240 mg | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 2 Day 1 | 1.91 Ratio | Geometric Coefficient of Variation 29 |
| Part 1A BMS-986207 800 mg | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 2 Day 1 | 2.04 Ratio | Geometric Coefficient of Variation 2 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 2 Day 1 | 1.97 Ratio | Geometric Coefficient of Variation 11 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 2 Day 1 | 1.35 Ratio | Geometric Coefficient of Variation 57 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 2 Day 1 | 1.93 Ratio | — |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 3 Day 1 | 1.40 Ratio | — |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 3 Day 1 | 1.47 Ratio | Geometric Coefficient of Variation 11 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 3 Day 1 | 1.19 Ratio | Geometric Coefficient of Variation 34 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 3 Day 1 | 1.46 Ratio | Geometric Coefficient of Variation 8 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 3 Day 1 | 1.40 Ratio | Geometric Coefficient of Variation 102 |
| Unknown | BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU) | Cycle 1 Day 1 | — Ratio | — |
Secondary
BMS-986207 Time to Maximum Concentration (Tmax)
Time to observed maximum concentration (Tmax) is defined as the amount of time in hours for a drug to reach the maximum concentration after administration.
Time frame: Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)
Population: All treated participants who have evaluable concentration-time data were included in the analysis. Only participants with evaluable concentration-time data at particular timepoint are considered in the analysis. Participant in Part 1A BMS-986207 Safety Run In did not meet criteria of evaluable concentration-time data hence not included in the analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A BMS-986207 Safety Run In | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 2.20 hours | Geometric Coefficient of Variation 169 |
| Part 1A BMS-986207 Safety Run In | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 2 Day 1 | 5.00 hours | — |
| Part 1A BMS-986207 20 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 1.07 hours | Geometric Coefficient of Variation 9 |
| Part 1A BMS-986207 20 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 2 Day 1 | 0.983 hours | — |
| Part 1A BMS-986207 80 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 1.00 hours | Geometric Coefficient of Variation 5 |
| Part 1A BMS-986207 80 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 2 Day 1 | 0.989 hours | Geometric Coefficient of Variation 3 |
| Part 1A BMS-986207 240 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 1.29 hours | Geometric Coefficient of Variation 59 |
| Part 1A BMS-986207 240 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 2 Day 1 | 4.92 hours | Geometric Coefficient of Variation 515 |
| Part 1A BMS-986207 800 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 2 Day 1 | 10.0 hours | Geometric Coefficient of Variation 190 |
| Part 1A BMS-986207 800 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 1.59 hours | Geometric Coefficient of Variation 72 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 2 Day 1 | 4.08 hours | Geometric Coefficient of Variation 291 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 1.11 hours | Geometric Coefficient of Variation 31 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 9.63 hours | Geometric Coefficient of Variation 3383 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 2 Day 1 | 2.51 hours | Geometric Coefficient of Variation 96 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 0.962 hours | Geometric Coefficient of Variation 5 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 2 Day 1 | 1.00 hours | — |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 1.47 hours | Geometric Coefficient of Variation 75 |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 3 Day 1 | 3.98 hours | — |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 3 Day 1 | 1.88 hours | Geometric Coefficient of Variation 82 |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 1.63 hours | Geometric Coefficient of Variation 110 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 3 Day 1 | 1.00 hours | Geometric Coefficient of Variation 0 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 1.94 hours | Geometric Coefficient of Variation 50 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 1.53 hours | Geometric Coefficient of Variation 62 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 3 Day 1 | 1.03 hours | Geometric Coefficient of Variation 9 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 3 Day 1 | 1.42 hours | Geometric Coefficient of Variation 37 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Time to Maximum Concentration (Tmax) | Cycle 1 Day 1 | 1.64 hours | Geometric Coefficient of Variation 23 |
Secondary
BMS-986207 Total Body Clearance (CLT)
Blood samples were collected for assessing CLT.
Time frame: Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)
Population: All treated participants who have evaluable concentration-time data were included in the analysis. Only participants with evaluable concentration-time data at particular timepoint are considered in the analysis. Participant in Part 1A BMS-986207 Safety Run In did not meet criteria of evaluable concentration-time data hence not included in the analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A BMS-986207 Safety Run In | BMS-986207 Total Body Clearance (CLT) | Cycle 2 Day 1 | 0.014 L/h | — |
| Part 1A BMS-986207 20 mg | BMS-986207 Total Body Clearance (CLT) | Cycle 2 Day 1 | 0.009 L/h | — |
| Part 1A BMS-986207 80 mg | BMS-986207 Total Body Clearance (CLT) | Cycle 2 Day 1 | 0.011 L/h | Geometric Coefficient of Variation 46 |
| Part 1A BMS-986207 240 mg | BMS-986207 Total Body Clearance (CLT) | Cycle 2 Day 1 | 0.011 L/h | Geometric Coefficient of Variation 35 |
| Part 1A BMS-986207 800 mg | BMS-986207 Total Body Clearance (CLT) | Cycle 2 Day 1 | 0.011 L/h | Geometric Coefficient of Variation 17 |
| Part 1A BMS-986207 1600 mg | BMS-986207 Total Body Clearance (CLT) | Cycle 2 Day 1 | 0.011 L/h | Geometric Coefficient of Variation 42 |
| Part 2A BMS-986207 800 mg (CRC) | BMS-986207 Total Body Clearance (CLT) | Cycle 2 Day 1 | 0.013 L/h | Geometric Coefficient of Variation 14 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | BMS-986207 Total Body Clearance (CLT) | Cycle 2 Day 1 | 0.015 L/h | — |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | BMS-986207 Total Body Clearance (CLT) | Cycle 3 Day 1 | 0.014 L/h | — |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | BMS-986207 Total Body Clearance (CLT) | Cycle 3 Day 1 | 0.011 L/h | Geometric Coefficient of Variation 23 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | BMS-986207 Total Body Clearance (CLT) | Cycle 3 Day 1 | 0.007 L/h | Geometric Coefficient of Variation 13 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Total Body Clearance (CLT) | Cycle 3 Day 1 | 0.011 L/h | Geometric Coefficient of Variation 46 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | BMS-986207 Total Body Clearance (CLT) | Cycle 3 Day 1 | 0.011 L/h | Geometric Coefficient of Variation 82 |
| Unknown | BMS-986207 Total Body Clearance (CLT) | Cycle 1 Day 1 | — L/h | — |
Secondary
Duration of Response
DOR is defined for participants who have a confirmed CR or PR as the date from first documented CR or PR per RECIST v1.1 to the date of the documentation of disease progression or death due to any cause, whichever is earlier. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose (Day 1) and up to 24 weeks
Population: All Treated Participants. Participants with CR or PR were included in the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Duration of Response | NA percentage of participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Duration of Response | NA percentage of participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Duration of Response | NA percentage of participants |
Secondary
Maximum Observed Concentration (Cmax) of BMS-986207
Cmax is defined as maximum plasma concentration of the drug.
Time frame: Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)
Population: All treated participants who have evaluable concentration-time data were included in the analysis. Only participants with evaluable concentration-time data at particular timepoint are considered in the analysis. Participant in Part 1A BMS-986207 Safety Run In did not meet criteria of evaluable concentration-time data hence not included in the analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A BMS-986207 Safety Run In | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 4952 ng/mL | Geometric Coefficient of Variation 34 |
| Part 1A BMS-986207 Safety Run In | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 2 Day 1 | 7540 ng/mL | — |
| Part 1A BMS-986207 20 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 27291 ng/mL | Geometric Coefficient of Variation 11 |
| Part 1A BMS-986207 20 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 2 Day 1 | 41200 ng/mL | — |
| Part 1A BMS-986207 80 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 78548 ng/mL | Geometric Coefficient of Variation 29 |
| Part 1A BMS-986207 80 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 2 Day 1 | 112632 ng/mL | Geometric Coefficient of Variation 36 |
| Part 1A BMS-986207 240 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 249112 ng/mL | Geometric Coefficient of Variation 16 |
| Part 1A BMS-986207 240 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 2 Day 1 | 349009 ng/mL | Geometric Coefficient of Variation 28 |
| Part 1A BMS-986207 800 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 2 Day 1 | 646106 ng/mL | Geometric Coefficient of Variation 7 |
| Part 1A BMS-986207 800 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 439192 ng/mL | Geometric Coefficient of Variation 15 |
| Part 1A BMS-986207 1600 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 2 Day 1 | 351683 ng/mL | Geometric Coefficient of Variation 29 |
| Part 1A BMS-986207 1600 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 259914 ng/mL | Geometric Coefficient of Variation 27 |
| Part 2A BMS-986207 800 mg (CRC) | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 48703 ng/mL | Geometric Coefficient of Variation 86 |
| Part 2A BMS-986207 800 mg (CRC) | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 2 Day 1 | 33291 ng/mL | Geometric Coefficient of Variation 18 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 67136 ng/mL | Geometric Coefficient of Variation 31 |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 2 Day 1 | 73100 ng/mL | — |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 510696 ng/mL | Geometric Coefficient of Variation 29 |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 3 Day 1 | 486000 ng/mL | — |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 3 Day 1 | 165211 ng/mL | Geometric Coefficient of Variation 20 |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 124997 ng/mL | Geometric Coefficient of Variation 27 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 3 Day 1 | 442029 ng/mL | Geometric Coefficient of Variation 41 |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 446640 ng/mL | Geometric Coefficient of Variation 20 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 215247 ng/mL | Geometric Coefficient of Variation 31 |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 3 Day 1 | 272349 ng/mL | Geometric Coefficient of Variation 65 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 3 Day 1 | 322580 ng/mL | Geometric Coefficient of Variation 40 |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Maximum Observed Concentration (Cmax) of BMS-986207 | Cycle 1 Day 1 | 257979 ng/mL | Geometric Coefficient of Variation 35 |
Secondary
Number of Participants With Positive Anti-BMS-986207-Antibodies Results
Participants who were treated with BMS-986207 and at least one post-baseline evaluable ADA assessment were considered in the analysis
Time frame: From first dose (Day 1) till 100 days after last dose (Up to approximately 27 months)
Population: All Treated Participants with Baseline and at Least One Post-baseline Evaluable ADA Assessment were included in the analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A BMS-986207 Safety Run In | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
| Part 1A BMS-986207 20 mg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
| Part 1A BMS-986207 80 mg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
| Part 1A BMS-986207 240 mg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
| Part 1A BMS-986207 800 mg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
| Part 1A BMS-986207 1600 mg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
| Part 2A BMS-986207 800 mg (CRC) | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 1 Participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 1 Participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
| Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Number of Participants With Positive Anti-BMS-986207-Antibodies Results | 0 Participants |
Secondary
Objective Response Rate (ORR)
ORR is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters
Time frame: From first dose (Day 1) and up to 24 weeks
Population: All Treated Participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1A BMS-986207 Safety Run In | Objective Response Rate (ORR) | 0.0 percentage of participants |
| Part 1A BMS-986207 20 mg | Objective Response Rate (ORR) | 0.0 percentage of participants |
| Part 1A BMS-986207 80 mg | Objective Response Rate (ORR) | 0.0 percentage of participants |
| Part 1A BMS-986207 240 mg | Objective Response Rate (ORR) | 0.0 percentage of participants |
| Part 1A BMS-986207 800 mg | Objective Response Rate (ORR) | 0.0 percentage of participants |
| Part 1A BMS-986207 1600 mg | Objective Response Rate (ORR) | 0.0 percentage of participants |
| Part 2A BMS-986207 800 mg (CRC) | Objective Response Rate (ORR) | 0.0 percentage of participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Objective Response Rate (ORR) | 0.0 percentage of participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Objective Response Rate (ORR) | 0.0 percentage of participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Objective Response Rate (ORR) | 0.0 percentage of participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Objective Response Rate (ORR) | 22.2 percentage of participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Objective Response Rate (ORR) | 33.3 percentage of participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Objective Response Rate (ORR) | 5.6 percentage of participants |
Secondary
Progression Free Survival Rate at Week 24
Progression Free Survival Rates at 24 weeks is defined as the percentage of participants who achieve PFS at 24 weeks. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Week 24
Population: All Treated Participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1A BMS-986207 Safety Run In | Progression Free Survival Rate at Week 24 | 100.0 percentage of participants |
| Part 1A BMS-986207 20 mg | Progression Free Survival Rate at Week 24 | 100.0 percentage of participants |
| Part 1A BMS-986207 80 mg | Progression Free Survival Rate at Week 24 | 66.7 percentage of participants |
| Part 1A BMS-986207 240 mg | Progression Free Survival Rate at Week 24 | 100.0 percentage of participants |
| Part 1A BMS-986207 800 mg | Progression Free Survival Rate at Week 24 | 75.0 percentage of participants |
| Part 1A BMS-986207 1600 mg | Progression Free Survival Rate at Week 24 | 100.0 percentage of participants |
| Part 2A BMS-986207 800 mg (CRC) | Progression Free Survival Rate at Week 24 | 70.0 percentage of participants |
| Part 1B BMS-986207 80 mg + Nivolumab 240 mg | Progression Free Survival Rate at Week 24 | 100.0 percentage of participants |
| Part 1B BMS-986207 240 mg + Nivolumab 240 mg | Progression Free Survival Rate at Week 24 | 100.0 percentage of participants |
| Part 1B BMS-986207 1600 mg + Nivolumab 480 mg | Progression Free Survival Rate at Week 24 | 75.0 percentage of participants |
| Part 1B: BMS-986207 480 mg + Nivolumab 480 mg | Progression Free Survival Rate at Week 24 | 93.3 percentage of participants |
| Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Progression Free Survival Rate at Week 24 | 66.7 percentage of participants |
| Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg | Progression Free Survival Rate at Week 24 | 61.1 percentage of participants |